Skip to Content
Merck
CN

Key Documents

View All Documentation

SML1657

Gefitinib

≥98% (HPLC), powder, EGFR TK inhibitor

Synonym(s):

N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine, ZD1839

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C22H24ClFN4O3
CAS Number:
184475-35-2
Molecular Weight:
446.90
UNSPSC Code:
12352200
PubChem Substance ID:
329825996
NACRES:
NA.77
MDL number:
MFCD04307832
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Gefitinib, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

room temp

SMILES string

COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4

InChI

1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

InChI key

XGALLCVXEZPNRQ-UHFFFAOYSA-N

Gene Information

human ... EGFR(1956)

Application

Gefitinib has been used :
  • To study its effective use in endometrial cancer therapy
  • Cell proliferation, cell cycle and apoptosis assays
  • Cell viability assay and colony formation assay

Biochem/physiol Actions

Gefitinib is a selective epidermal growth factor receptor tyrosine kinase (EGFR TK) inhibitor. Gefitinib has antineoplastic activity, and has been approved for the treatment on non-small cell lung cancer (NSCLC).
Gefitinib has a higher affinity for ATP (adenosine triphosphate) binding site in the EGFR tyrosine kinase domain than ATP. Hence, gefitinib is known to inhibit the progression of endometrial cancer.

Still not finding the right product?

Explore all of our products under Gefitinib

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
076M4739V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Roy S Herbst et al.
The oncologist, 7 Suppl 4, 9-15 (2002-08-31)
Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis for this patient population remains poor. Novel biologically targeted agents currently in development have the potential for greater efficacy against NSCLC, and possibly less
P M Ellis et al.
Current oncology (Toronto, Ont.), 22(3), e183-e215 (2015-06-20)
This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients-unselected, selected, and molecularly selected-in three treatment settings: first line, second line, and maintenance. Ninety-six randomized controlled trials
The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma.
Qiu M, et al.
Cancer Research, 78(11), 2839-2851 (2018)
View All Related Papers

Global Trade Item Number

SKUGTIN
SML1657-10MG04061832964119
SML1657-50MG04061832964126